longbridgelongbridge
  • Platform Features
    Features
    Investment ProductsPrivate Wealth ManagementTrading ToolsMarket Data ServicesAnalysis ToolsNews ServicesFor Developers
    Account Types
    For IndividualsFor Institutions
  • Café
longbridge
© 2026 Longbridge|Terms of ServicePrivacy Policy

Vivani Medical

VANI

----
Start trading
OverviewOverviewNewsNewsPostsPostsFinancialsFinancialsForecastForecastValuationValuationShareholdersShareholdersProfileProfile
LongbridgeAI

Current ValuationThe current P/E ratio is -4.22, below the reasonable range, cheaper than 82.87% of the time in the past 5 years, and the industry ranks 110/175, the industry Median -0.85.

-4.22xP/E
$1.23Stock price
$-0.29Earnings per share
-4.22xP/E
Stock price$1.23Earnings per share$-0.29

Historical Valuation

P/E ratioTypical rangeMedian
P/E ratio
-3.39x
Typical range
-4.11x–-2.69x

Peer P/E ratio Comparison

It displays how the company's P/E ratio compares to top companies within its industry.
012243648

The industry median valuation is currently at or below 0 and may not serve as a meaningful benchmark.

Industry P/E ratio Comparison

This shows the distribution of companies by P/E ratio range and their projected earnings per share growth for the next fiscal year.
0x30x60x90x120x150x
P/E ratio
Name/Symbol
BAXUSBaxter
-11.42x141.71%$12.14B
GKOSUSGlaukos
-48.14x75.37%$9.05B
TFXUSTeleflex
-5.00x118.39%$5.16B
PLSEUSPulse Biosciences
-46.31x27.55%$3.71B
IRTCUSIRhythm
-264.12x71.96%$3.68B
AXGNUSAxogen
-75.76x31.25%$2.54B
BFLYUSButterfly Network
-32.73x34.41%$2.45B
ASSTUSStrive
-2.06x63.23%$2.00B
NVCRUSNovocure
-12.74x2.52%$1.89B
ATECUSAlphatec
-14.08x41.67%$1.55B
KMTSUSKestra Medical Tech
-9.97x0.94%$1.49B
DRTSUSAlpha Tau Medical
-14.48x--$1.34B
IARTUSIntegra LifeSciences
-166.89x109.50%$1.21B
BBNXUSBeta Bionics
-16.01x13.59%$1.17B
AORTUSArtivion
-359.52x266.67%$1.15B
TNDMUSTandem Diabetes
-18.00x77.75%$1.14B
ENOVUSEnovis
-0.95x100.97%$1.05B
PRCTUSPROCEPT BioRobotics
-9.44x3.47%$1.04B
CBLLUSCeribell
-13.74x35.15%$906.49M
SIBNUSSI-BONE
-56.97x8.85%$833.63M

Risk Warning

Timeframes using financial data from S&P Global. The feature provides key metrics such as price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S) ratios, and dividend yield. For reference only and does not constitute investment advice.